Citius Pharmaceuticals (CTXR) Interest Coverage Ratio (2010 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Interest Coverage Ratio came in at 50.63 in Q2 2026, up 0.76% on a YoY basis from 50.25 in Q2 2025, and up 94.81% quarter-over-quarter from 974.68 in Q1 2026.
Powered by 
Analysis
Citius Pharmaceuticals (CTXR) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has reported Interest Coverage Ratio for 17 consecutive years, with 50.63 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Interest Coverage Ratio rose 0.76% year-over-year to 50.63; the trailing twelve-month figure through Jun 2026 stood at 119.0 (up 48.17% YoY), and the FY2025 full-year result was 7.15, changed N/A from the prior year.
- Interest Coverage Ratio rose to 50.63 in Q2 2026 per CTXR's latest filing, from 974.68 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 2.76 in Q1 2022 and bottomed at 14178.91 in Q2 2024.
- Historically, Interest Coverage Ratio has averaged 1048.35 across 5 years, with a median of 42.84 in 2022.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio soared 99.74% in 2022, then sank 133199.45% in 2024.
- Over 5 years, Interest Coverage Ratio stood at 42.84 in 2022, then soared by 42.53% to 24.62 in 2023, then sank by 57494.22% to 14178.91 in 2024, then soared by 99.59% to 57.99 in 2025, then climbed by 12.69% to 50.63 in 2026.
- According to Business Quant data, Interest Coverage Ratio over the past three periods registered 50.63, 974.68, and 57.99 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.22 Bn | 620.47 Bn | 17.26 Bn | 25.41 |
| 2 | AbbVie | 446.28 Bn | 439.71 Bn | 12.70 Bn | - |
| 3 | Merck | 357.56 Bn | 350.42 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 268.11 Bn | 260.42 Bn | 11.24 Bn | 10.28 |
| 5 | Pfizer | 156.86 Bn | 145.17 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.10 Bn | 44.72 Bn | 10.79 Bn | 3.65 |
| 7 | Revolution Medicines | 43.01 Bn | 43.01 Bn | - | -21.24 |
| 8 | Incyte | 24.82 Bn | 20.28 Bn | 1.57 Bn | 1,199.14 |
| 9 | United Therapeutics | 21.39 Bn | 18.73 Bn | 683.80 Mn | 114.07 |
| 10 | Citius Pharmaceuticals | 15.27 Mn | 15.27 Mn | 1.00 Mn | -50.63 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.63 |
| Mar 31, 2026 | -974.68 |
| Dec 31, 2025 | -57.99 |
| Sep 30, 2025 | -88.33 |
| Jun 30, 2025 | -51.02 |
| Jun 30, 2024 | -14,178.91 |
| Mar 31, 2024 | -10.28 |
| Dec 31, 2023 | -24.62 |
| Sep 30, 2023 | -180.15 |
| Jun 30, 2023 | -10.64 |
| Mar 31, 2023 | -14.23 |
| Dec 31, 2022 | -42.84 |
| Sep 30, 2022 | -8.68 |
| Jun 30, 2022 | -29.43 |
| Mar 31, 2022 | -2.76 |
| Jun 30, 2021 | -2,041.07 |
| Mar 31, 2021 | -1,052.22 |
| Dec 31, 2020 | -2,055.55 |
| Sep 30, 2020 | -1,197.79 |
| Jun 30, 2020 | -1,104.57 |